The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
Sign Up to like & getrecommendations! Published in 2018 at "American Heart Journal"
DOI: 10.1016/j.ahj.2018.01.012
Abstract: Background: Dapagliflozin is a sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitor that reduces blood glucose in patients with type 2 diabetes mellitus (T2DM) by promoting glycosuria via inhibiting urinary glucose reabsorption. In addition to improving blood glucose control,… read more here.
Keywords: composite death; trial; declare timi; cardiovascular events ... See more keywords
EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)31287-0
Abstract: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58), dapagliflozin reduced the risk of the composite of cardiovascular death (CVD) or hospitalization for heart failure (HHF) and of adverse renal outcomes in… read more here.
Keywords: dapagliflozin cardiovascular; patients type; effects dapagliflozin; cardiovascular outcomes ... See more keywords
Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58
Sign Up to like & getrecommendations! Published in 2020 at "Circulation"
DOI: 10.1161/circ.142.suppl_3.16139
Abstract: Background: Patients (pts) with type 2 diabetes mellitus (T2DM) are at increased risk of heart failure (HF); however, the underlying mechanisms by which T2DM contributes to HF are incompletely understood. Hypothesis: We aimed to identify… read more here.
Keywords: declare timi; risk; type diabetes; diabetes mellitus ... See more keywords
Class effects of SGLT2 inhibitors on cardiorenal outcomes
Sign Up to like & getrecommendations! Published in 2019 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-019-0903-4
Abstract: BackgroundTo summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing… read more here.
Keywords: class effects; credence; canvas; empa reg ... See more keywords
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes care"
DOI: 10.2337/dc22-1318
Abstract: OBJECTIVE The cardiorenal benefits of adding sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy for patients on insulin, particularly those on intensive regimens that include short-acting (SA) insulin, have not been explored. RESEARCH DESIGN AND METHODS In… read more here.
Keywords: safety; insulin; insulin regimens; insulin users ... See more keywords